Make your money go further for just 25p per day

More than Money: Circassia

Circassia (LON: CIR) is a rare example of a small drug maker with a plan B for when drugs trials go wrong. That plan B (use its strong commercial platform to sell respiratory drugs globally) has now landed it with a second drug approval in the US and a label expansion which leaves its first US drug as the best-in-class for patients with chronic obstructive pulmonary disease (COPD). It has been ten months since Circassia filed for approval and the group’s chief executive Steve Harris was all ready to enjoy a well-earned holiday when both approvals came through on Friday. But he was still able to take some time out from his break to talk me through the good news.

Sign up for more great content

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

Have your say

Log in or register to view or add comments.

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Circassia

Outstanding results, but are they repeatable

22/03/2022 · Company Insights

An elderly AIM company covered here, which traces its roots back to the 19th century, has…


Strong updates to enjoy

13/01/2022 · Company Insights

Results and updates covered here include those of several consistent (and highly-rated) performers, but a potential…


More Podcasts

More than Money: Chris Boxall on the AIM sell-off

04/03/2022

More than Money: Harvey Sinclair

03/03/2020 · eEnergy

More than Money: Andrew Vaughan

25/02/2020

Sign-up to our free email updates

SIGN UP